TrialPath

12 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

12 studies on the map

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) — GSK Investigational Site, AnnistonPRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis — Purushotham & Akther Kotha MD, Inc., La MesaRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamSafety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial — AARA Clinical Research, GlendaleA Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 — Local Institution - 0001, FarmingtonClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaSafety of the Herpes Zoster Subunit Vaccine in Lupus — NYU Langone Health, New YorkDapagliflozin in Active Lupus Nephritis — Massachusetts General Hospital, BostonProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) — Cincinnati Children's Hospital Medical Center, CincinnatiTrial of Belimumab in Early Lupus — Feinstein Institute, ManhassetProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users — Research Site, Las Vegas